A voluntary agreement between the Government and the pharmaceutical industry.
The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues including medicines regulation, UK and EU trading relationships, access to talent, and the future of UK science.
The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines.
The Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have welcomed the publication of "Continuity in the availability of goods for the EU and the UK", published today by the UK Government's Department for Exiting the European Union.
As a membership organisation we work with our member companies, and the expertise of the specialists they employ, to develop and present our points of view to UK and European governments, the public and to other stakeholders.
In this interview with pharmaphorum, ABPI CEO Stephen Whitehead discusses the role of the organisation and his thoughts on some of the challenges and opportunities faced by industry.
0:15 – Why Stephen returned to pharma and what he learned from outside
1:04 – How the ABPI can support the industry through a period of change
2:04 – Influence of the ABPI beyond the UK on the broader global scene
2:56 – Stephen’s vision for the future of pharma
4:15 – Addressing the reputational issues faced by pharma
5:34 – Key game changers for pharma and impact on the ABPI
6:38 – Digital communications
8:39 – How the UK can remain a key global centre for pharma
10:09 – Stephen’s ambition for the ABPI by the end of his tenure